


**Ticker:** CTM AU      **4Q25 cash:** A\$25m      **Project:** Jaguar / Boi Novo / Jambreiro  
**Market cap:** A\$353m      **Price:** A\$0.63/sh      **Country:** Brazil  
**REC. (unc):** BUY      **TARGET (unc):** A\$1.50/sh      **RISK RATING (unc):** HIGH

Yesterday's Jambreiro pilot plant testwork provides a nice follow-on to 2Q24 bench scale testing, seeing improved average metallurgical (89.3% vs 89.1%) and mass (40.3% vs 37.6%) recoveries, and highlighting a finished concentrate squarely in the green steel/DR-EAF market, a structural premium segment. The project works not because it recovers a lot of mass, but because it produces a scarce premium DR product (67.8% Fe, 1.93% SiO<sub>2</sub>+Al<sub>2</sub>O<sub>3</sub>, 0.02% P) at high metallurgical recovery, so most iron value is captured while cheap mining and strong logistics support margins. Importantly, new tests now suggests that tailings co-disposal and simplified dewatering could further reduce project capital/operating intensity. That is, with the blended 9:1 tails:slimes seeing a ~24% moisture content, the expected operating ratio of ~13.5:1 should result in even lower final moisture, potentially eliminating the need for dedicated slimes filter press and separate deposition of a dry stacked slimes tails. Recall the 2020 study update (based on the 2019 PFS), outlined an 18-year, 1 Mtpa project requiring an initial A\$58.8M capex, delivering an after-tax NPV of A\$147.2M and a 37% IRR – hence we see further upside here on incorporating premium DR pricing in addition to reduced costs. Bottom line, the testwork materially de-risks the project and shifts the opportunity to securing commercial terms.

As such, we maintain our **BUY rating and our A\$1.50/sh price target** based on 0.5xNAV for Jaguar. While advancing permitted Jaguar to a production scenario remains in focus with project financing (incl. relevant offtake discussions) key now to kicking off construction. The name trades cheaply at just 0.21x NAV, hence we see deep value on any future potential commercial terms at Jambreiro or discovery flyer at Boi/Rio Novo – both entirely upside to Jaguar (one of the largest, fully-derisked, permitted, undeveloped nickel sulphide assets globally). All that ahead of any additional nickel price momentum, with Indonesian supply cut-backs already forecasted for this year with the national target of 260Mt down from 379Mt in 2025.

**Figure 1. New Jambreiro flowsheet to produce DR concentrate**



Source: Centaurus Metals

**Jambreiro pilot testwork confirms high-purity DRPF concentrate supporting off-take discussions**

Yesterday, Centaurus reported pilot plant testwork from the 100%-owned Jambreiro Iron Ore Project (Brazil). Testing on a 1.4t bulk composite feed sample grading 30.61% Fe, 50.97% SiO<sub>2</sub>, 3.1% Al<sub>2</sub>O<sub>3</sub> 0.03% P and 1.51 LOI produced over 0.5t of high-purity direct-reduction pellet feed (DRPF) concentrate grading 67.8% Fe with low impurities (1.45% SiO<sub>2</sub>, 0.48% Al<sub>2</sub>O<sub>3</sub>; 1.93% combined (vs <2% DR pellet feed product target), 0.02% P), meeting DR steelmaking specifications. The product achieved 40.3% mass recovery and 89.3% metallurgical recovery, confirming consistent DR production capability and refining the flowsheet, including magnetic circuit upgrades that improved recovery and grade. Concentrate filtering and grinding tests resulted in leaf tests of 1.42t/m<sup>2</sup> with and without flocculant, bond work index 24.24kwh/t and PRED test 12.84kwh/t.

Tailings filtration and drainage tests resulted in moisture of 24% from testing 100% spiral tails (60% moisture) and 9:1 spiral tails (60% moisture):thickened slimes (80% moisture) mixture, suggesting co-disposal with mine waste and potential capex reductions from removing need for slimes filter press and separate deposition of dry stacked slimes tails. All three components of the future co-disposal waste piles (slimes, rougher spirals tails and waste rock) will be geotechnically tested. Ongoing test results will support off-take discussions and project re-licensing.

### Why we like Centaurus

1. Only >1.2Mt Ni metal, <US\$500m capex, pitable nickel sulphide junior globally
2. One of few high-grade nickel sulphide developers retaining 100% of its offtake rights
3. CO<sub>2</sub> / energy security value with <1/10<sup>th</sup> the CO<sub>2</sub> of laterites, and location outside Russia
4. Taking 'vanilla' concentrate route leaving room for down-stream POX optionality
5. 10Y 75% tax-breaks in well known mining jurisdiction (no rainforest, RAP, indigenous)

### Catalysts

- 2026: Advance Jambreiro offtake discussions and licensing
- 2026: Boi/Rio-Novo exploration
- 1H26 / 2H28: Final investment decision / production start

### Research

**Brandon Gaspar** (Toronto) m +1 437 533 3142 [bgaspar@scp-rf.com](mailto:bgaspar@scp-rf.com)

**Eleanor Magdzinski** (Toronto) m +1 705 669 7456 [emagdzinski@scp-rf.com](mailto:emagdzinski@scp-rf.com)

**Ken Ilodibe** (Toronto) m +1 204 963 3423 [kilodibe@scp-rf.com](mailto:kilodibe@scp-rf.com)

**Omeet Singh** (Toronto) m +1 647 527 7509 [osingh@scp-rf.com](mailto:osingh@scp-rf.com)

**Moatasm Almaouie** (Toronto) m +1 780 299 5151 [malmaouie@scp-rf.com](mailto:malmaouie@scp-rf.com)

Ticker: CTM AU	Price / mkt cap:	A63c/sh / A\$353m	P/NAV today:	0.21x	Country: Brazil
Author: B Gaspar	Recd/0.5xNAV7% PT:	BUY, A\$1.50/sh	1xNAV <sub>2025</sub> FF FD:	A\$2.69/sh	Asset: Jaguar

Commodity price	CY24A	CY25E	CY26E	CY27E	CY28E
Ni price (US\$/t)	17,061	15,579	17,726	20,408	20,944
Ni price (US\$/t, payable)	13,649	12,463	14,181	16,326	16,755
<b>1xNAV project valuation*</b>	<b>A\$m</b>	<b>o/ship</b>	<b>NAVx</b>	<b>A\$/sh</b>	
Jaguar OP NPV (build start)	1,445	100%	1.0x	2.38	
Jaguar UG, 50% risked	141	100%	1.0x	0.23	
Expln & resources ex reserve @ 1% insitu	190	100%	1.0x	0.31	
4Q25 cash	25	100%	1.0x	0.04	
Cash from ITM options	15.5	100%	1.0x	0.03	
<b>1XNAV A\$ @ 2Q25</b>	<b>1,816</b>			<b>2.99</b>	

\*Build start, ex fin. cost + G&A, dil. for optns not build P/NAV today: 0.21x

Asset value: 1xNPV project @ build start (A\$m, ungeared)*					
	7.50/lb	8.50/lb	9.50/lb	10.50/lb	11.50/lb
Group NAV (A\$m)	16,535	18,739	20,944	23,149	25,353
9.0% discount	889	1,232	1,574	1,917	2,259
7.0% discount	1,043	1,429	1,816	2,202	2,588
5.0% discount	1,232	1,671	2,111	2,551	2,990
Ungeared project IRR:	21%	27%	33%	38%	43%
Group NAV (A\$/sh)	16,535	18,739	20,944	23,149	25,353
9.0% discount	1.46	2.03	2.59	3.16	3.72
7.0% discount	1.72	2.35	2.99	3.63	4.26
5.0% discount	2.03	2.75	3.48	4.20	4.92

\*Project level NPV, excl finance costs and central SGA, discounted to build start


SOTP company valuation^	Dec-25	Dec-26	Dec-27	Jun-28	Dec-29
Jaguar NPV	1,416	1,743	2,190	2,346	2,173
Resources ex reserve + UG	331	331	331	331	331
Central G&A & fin costs	(159)	(152)	(110)	(84)	(23)
Net cash prior quarter	27.5	20.7	(328.0)	(439.6)	(129.7)
Cash from ITM options	15.5	15.5	15.5	15.5	15.5
NAV (A\$m)	1,632	1,957	2,099	2,169	2,367
FD share count (m)	606	607	607	607	607
1xNAV7%/sh FF FD (A\$/sh)	2.69	3.22	3.46	3.57	3.90

Exit value: 1xNAV/sh company @ first production (A\$, geared)^					
	7.50/lb	8.50/lb	9.50/lb	10.50/lb	11.50/lb
Group NAV (A\$m)	16,535	18,739	20,944	23,149	25,353
9.0% discount	1,143	1,557	1,971	2,385	2,800
7.0% discount	1,268	1,718	2,169	2,619	3,070
5.0% discount	1,417	1,911	2,405	2,898	3,392

Exit value: 1xNAV/sh company @ first production (A\$, geared)^					
1xNAV (A\$/sh)	16,535	18,739	20,944	23,149	25,353
9.0% discount	1.88	2.56	3.25	3.93	4.61
7.0% discount	2.09	2.83	3.57	4.31	5.06
5.0% discount	2.33	3.15	3.96	4.77	5.59

Production	Y1	Y2	Y3	Y4	Y5
Jaguar production (000kt Ni)	14.8	23.5	21.1	23.9	18.2
C1 cost (US\$/t Ni)	5,745	5,961	6,242	6,222	7,457
AISC cost (US\$/t Ni)	7,240	7,482	7,702	7,757	9,055

AISC = C1 + sustaining capex + central G&A, C3 = AISC + depreciation



Source: SCP estimates

Resource/Inventory	Mt	NiEq %	Mt	Ni %
	2Q24 JORC		Reserves	
M&I	112.6	0.95%	OP:	52.0 0.78%
Inferred	25.7	0.97%	UG:	- -
	138.2	0.95%	Total	52.0 0.78%

Funding: uses	Funding: sources			
Capex (A\$m)	584.0	2Q25 cash (A\$m)		24.6
Drilling/FS cost (A\$m)	2.8	SCPe debt (A\$m)		467.2
Working cap >DFS (A\$m)	-	SCPe equity at spot (A\$m)		22.4
G&A and fin. cost (A\$m)	36.1	Total sources (A\$m)		514.2
Total uses: group (A\$m)	622.9	Buffer (A\$m)		-108.6

Share data (m)	Basic	FD	FF FD		
Shares (m)	564.6	607.3	643.2		
Ratio analysis	CY24A	CY25E	CY26E	CY27E	CY28E
Shares out (m)	496.7	562.8	564.6	564.6	564.6
EPS (Ac/sh)	-	-	-	-	21.5
CFPS pre w/c (A\$/sh)	-	-	-	-	7.2
EV (A\$m)	292.4	325.3	415.6	744.7	671.5
FCF yield (%)	-	-	-	-	21%
PER (x)	-	-	-	-	2.9x
P/CF (x)	-	-	-	-	4.8x
EV/EBITDA (x)	-	-	-	-	3.0x

Income statement	CY24A	CY25E	CY26E	CY27E	CY28E
Revenue (A\$m)	-	-	-	-	381.9
COGS (A\$m)	-	-	-	-	152.3
<b>Gross profit (A\$m)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>229.6</b>
G&A (A\$m)	4.3	4.2	4.0	4.0	4.0
Exploration (A\$m)	16.9	10.0	-	-	-
Finance costs (A\$m)	-	-	18.2	49.3	48.2
Tax (A\$m)	(3.5)	-	-	-	24.9
Other (A\$m)	0.2	0.2	(0.4)	(0.5)	31.1
<b>Net income (A\$m)</b>	<b>(17.8)</b>	<b>(14.4)</b>	<b>(21.7)</b>	<b>(52.8)</b>	<b>121.4</b>

Cash flow statement	CY24A	CY25E	CY26E	CY27E	CY28E
EBITDA (A\$m)	(22.5)	(14.9)	(4.0)	(4.0)	225.6
Add share based (A\$m)	1.1	0.5	-	-	-
Net change WC (A\$m)	(0.6)	0.4	-	1.2	32.7
<b>Cash flow ops (A\$m)</b>	<b>(15.8)</b>	<b>(14.2)</b>	<b>(21.7)</b>	<b>(54.0)</b>	<b>119.9</b>
PP&E + sust. (A\$m)	0.3	0.0	275.0	275.0	46.7
PP&E - expl'n (A\$m)	0.1	-	-	-	-
<b>Cash flow inv. (A\$m)</b>	<b>(0.4)</b>	<b>(0.3)</b>	<b>(275.0)</b>	<b>(275.0)</b>	<b>(46.7)</b>
Share issue (A\$m)	0.4	22.4	207.5	-	-
Debt draw (repay) (A\$m)	-	-	315.0	152.2	(116.8)
<b>Cash flow fin. (A\$m)</b>	<b>0.4</b>	<b>22.4</b>	<b>522.5</b>	<b>152.2</b>	<b>(116.8)</b>
Net change in cash (A\$m)	(16.4)	8.1	225.8	(176.8)	(43.6)

Balance sheet	CY24A	CY25E	CY26E	CY27E	CY28E
Cash (A\$m)	18.0	26.5	252.2	75.4	31.8
Acc rec. + invet. (A\$m)	14.2	14.2	14.2	13.4	62.8
PP&E & expl'n (A\$m)	20.7	10.7	285.7	560.7	576.2
<b>Total assets (A\$m)</b>	<b>39.5</b>	<b>51.3</b>	<b>552.1</b>	<b>649.5</b>	<b>670.8</b>
Debt (A\$m)	-	-	315.0	467.2	350.4
Accounts payable (A\$m)	2.4	2.0	2.0	-	16.7
Others (A\$m)	18.6	27.3	253.0	75.4	81.2
Total liabilities (A\$m)	4.1	6.1	321.1	471.3	371.2
Shareholders' equity (A\$m)	282.5	305.0	512.5	512.5	512.5
Reserves (A\$m)	(7.7)	(6.8)	(6.8)	(6.8)	(6.8)
Retained earnings (A\$m)	(239.4)	(252.9)	(274.7)	(327.5)	(206.1)
<b>Liabilities + equity (A\$m)</b>	<b>39.5</b>	<b>51.3</b>	<b>552.1</b>	<b>649.5</b>	<b>670.8</b>

**DISCLOSURES & DISCLAIMERS**

This research report (as defined under CIRO Rule 3600, Part B) is issued and approved for distribution in Canada by SCP Resource Finance LP ("SCP"), an investment dealer who is a member of The Canadian Investment Regulatory Organization ("CIRO") and the Canadian Investor Protection Fund ("CIPF"). This research report is provided to retail clients and institutional investors for information purposes only. The opinions expressed in this report are the opinions of the author and readers should not assume they reflect the opinions or recommendations of SCP's research department. The information in this report is drawn from sources believed to be reliable but the accuracy or completeness of the information is not guaranteed, nor in providing it does SCP or persons assume any responsibility or liability whatsoever. This report is not to be construed as an offer to sell or a solicitation of an offer to buy any securities. SCP accepts no liability whatsoever for any loss arising from any use or reliance on this research report or the information contained herein. Past performance is not a guarantee of future results, and no representation or warranty, expressed or implied, is made regarding future performance of any security mentioned in this research report. The price of the securities mentioned in this research report and the income they generate may fluctuate and/or be adversely affected by market factors or exchange rates, and investors may realize losses on investments in such securities, including the loss of investment principal. Furthermore, the securities discussed in this research report may not be liquid investments, may have a high level of volatility or may be subject to additional and special risks associated with securities and investments in emerging markets and/or foreign countries that may give rise to substantial risk and are not suitable for all investors. SCP may participate in an underwriting of, have a position in, or make a market in, the securities mentioned herein, including options, futures or other derivatives instruments thereon, and may, as a principal or agent, buy or sell such products.

**DISSEMINATION OF RESEARCH:** SCP's research is distributed electronically through email or available in hard copy upon request. Research is disseminated concurrently to a pre-determined list of clients provided by SCP's Institutional Sales Representative and retail Investment Advisors. Should you wish to no longer receive electronic communications from us, please contact [unsubscribe@scp-rf.com](mailto:unsubscribe@scp-rf.com) and indicate in the subject line your full name and/or corporate entity name and that you wish to unsubscribe from receiving research.

**RESEARCH ANALYST CERTIFICATION:** Each Research Analyst and/or Associate who is involved in the preparation of this research report hereby certifies that:

- The views and recommendations expressed herein accurately reflect his/her personal views about any and all of the securities or issuers that are the subject matter of this research report;
- His/her compensation is not and will not be directly related to the specific recommendations or view expressed by the Research analyst in this research report;
- They have not affected a trade in a security of any class of the issuer within the 30-day period prior to the publication of this research report;
- They have not distributed or discussed this Research Report to/with the issuer, investment banking group or any other third party except for the sole purpose of verifying factual information; and
- They are unaware of any other potential conflicts of interest.

**UK RESIDENTS:** SCP Partners UK Limited ("SCP UK") is an appointed representative of PillarFour Securities LLP which is authorized and regulated by the Financial Conduct Authority. This document has been approved under section 21(1) of the FMSA 2000 by PillarFour Securities LLP ("PillarFour") for communication only to eligible counterparties and professional clients as those terms are defined by the rules of the Financial Conduct Authority. Its contents are not directed at UK retail clients. PillarFour does not provide investment services to retail clients. PillarFour publishes this document as non-independent research which is a marketing communication under the Conduct of Business rules. It has not been prepared in accordance with the regulatory rules relating to independent research, nor is it subject to the prohibition on dealing ahead of the dissemination of investment research. It does not constitute a personal recommendation and does not constitute an offer or a solicitation to buy or sell any security. SCP UK and PillarFour consider this note to be an acceptable minor non-monetary benefit as defined by the FCA which may be received without charge. This is because the content is either considered to be commissioned by SCP UK's clients as part of their advisory services to them or is short term market commentary. Neither SCP UK nor PillarFour nor any of its directors, officers, employees or agents shall have any liability, howsoever arising, for any error or incompleteness of fact or opinion in it or lack of care in its preparation or publication; provided that this shall not exclude liability to the extent that this is impermissible under the law relating to financial services. All statements and opinions are made as of the date on the face of this document and are not held out as applicable thereafter. This document is intended for distribution only in those jurisdictions where PillarFour is permitted to distribute its research.

**IMPORTANT DISCLOSURES FOR U.S. PERSONS:** This research report was prepared by SCP Resource Finance LP ("SCP"), a company authorized to engage in securities activities in Canada. SCP is not a registered broker/dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only SCP Real Assets, LLC ("SCP-RA"), a broker dealer in the United States registered with the Securities Exchange Commission ("SEC"), the Financial Industry Authority ("FINRA"), and a member of the Securities Investor Protection Corporation ("SIPC"). Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through SCP.

SCP-RA accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor. The analyst whose name appears in this research report is not licensed, registered, or qualified as a research analyst with FINRA and may not be an associated person of SCP-RA and, therefore, may not be subject to applicable restrictions under FINRA Rule 2241 regarding communications by a research analyst with a subject company, public appearances by the research analyst, and trading securities held by a research analyst account. To make further inquiries related to this report, United States residents should contact their SCP-RA representative.

**ANALYST CERTIFICATION / REGULATION AC:** The analyst and associate certify that the views expressed in this research report accurately reflect their personal views about the subject securities or issuers. In addition, the analyst and associate certify that no part of their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

**SCP RESOURCE FINANCE EXPLANATION OF RECOMMENDATIONS:** Should SCP issue research with recommendations, the research rating guidelines will be based on the following recommendations:

**BUY:** The stocks total returns are expected to be materially better than the overall market with higher return expectations needed for more risky securities markets

**NEUTRAL:** The stock's total returns are expected to be in line with the overall market

**SELL:** The stocks total returns are expected to be materially lower than the overall market

**TENDER:** The analyst recommends tendering shares to a formal tender offering

**UNDER REVIEW:** The stock will be placed under review when there is a significant material event with further information pending; and/or when the research analyst determines it is necessary to await adequate information that could potentially lead to a re-evaluation of the rating, target price or forecast; and/or when coverage of a particular security is transferred from one analyst to another to give the new analyst time to reconfirm the rating, target price or forecast.

**NOT RATED (N/R):** The stock is not currently rated

Research Disclosure		Response
1	SCP collectively beneficially owns 1% or more of any class of the issuer's equity securities <sup>1</sup>	NO
2	The analyst or any associate of the analyst responsible for the report or recommendation or any individual directly involved in the preparation of the report holds or is short any of the issuer's securities directly or through derivatives	NO
3	An SCP partner, director, officer or analyst involved in the preparation of a report on the issuer, has during the preceding 12 months provided services to the issuer for remuneration other than normal course investment advisory or trading execution services	NO
4	SCP has provided investment banking services for the issuer during the 12 months preceding the date of issuance of the research report or recommendation	YES
5	Name of any director, officer, employee or agent of SCP who is an officer, director or employee of the issuer, or who serves in an advisory capacity to the issuer	NO
6	SCP is making a market in an equity or equity related security of the issuer	NO
7	The analyst preparing this report received compensation based upon SCP's investment banking revenue for the issuer	NO
8	The analyst has conducted a site visit and has viewed a major facility or operation of the issuer	NO
9	The analyst has been reimbursed for travel expenses for a site visit by the issuer	NO

**SCP Resource Finance Equity Research Ratings:**

Summary of Recommendations as of February 2026	
BUY:	56
HOLD:	0
SELL:	0
UNDER REVIEW:	0
TENDER:	0
NOT RATED:	0
TOTAL	56

<sup>1</sup> As at the end of the month immediately preceding the date of issuance of the research report or the end of the second most recent month if the issue date is less than 10 calendar days after the end of the most recent month